Prelude appoints Jane Huang as President & CMO; updates pipeline prioritizing PRT811 and IV PRT1419

Prelude Therapeutics Inc

Appoints Jane Huang President & CMO effective April 4, 2022; compensation: $525k base, 50% bonus target, 150k RSUs, 460k options.
Prioritizes PRT811 over PRT543 for PRMT5 program due to superior safety & brain penetration; expansion cohort data in 2H2022.
New pipeline candidate PRT3645, a highly brain-penetrant CDK4/6 inhibitor; IND submission planned mid-2022.
IV formulation of MCL1 inhibitor PRT1419 prioritized; combination trial with venetoclax starts mid-2022; RP2D by 2H2022.
SMARCA2/BRM degrader progress; IND submission planned by year-end 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jane Huang

President and Chief Medical Officer

PRLD · Prelude Therapeutics Inc

Effective: 2022-04-04
Filed: March 9, 2022, 6:59 PM ET

the Board of Directors of the Company (the “ Board ”) appointed Jane Huang, M.D., age 49, as the President and Chief Medical Officer of the Company, effective on or about April 4, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jane Huang was appointed as President and Chief Medical Officer at Prelude Therapeutics Inc.

Action: appointed
Role: President and Chief Medical Officer

Exact text from the filing

the Board of Directors of the Company (the “ Board ”) appointed Jane Huang, M.D., age 49, as the President and Chief Medical Officer of the Company, effective on or about April 4, 2022

View on SEC.gov

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0001193125-22-070007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.